Tennessee Valley Asset Management Partners Makes New $36,000 Investment in Pfizer Inc. (NYSE:PFE)

Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,236 shares of the biopharmaceutical company’s stock, valued at approximately $36,000.

Several other large investors also recently bought and sold shares of the stock. Essex LLC increased its holdings in Pfizer by 14.8% during the 4th quarter. Essex LLC now owns 75,763 shares of the biopharmaceutical company’s stock worth $2,181,000 after purchasing an additional 9,749 shares during the period. Braun Bostich & Associates Inc. purchased a new stake in Pfizer during the 4th quarter worth about $290,000. Wealth Effects LLC increased its holdings in Pfizer by 1.5% during the 4th quarter. Wealth Effects LLC now owns 57,321 shares of the biopharmaceutical company’s stock worth $1,650,000 after purchasing an additional 828 shares during the period. Sutton Place Investors LLC purchased a new stake in Pfizer during the 4th quarter worth about $802,000. Finally, Sapient Capital LLC purchased a new stake in Pfizer during the 4th quarter worth about $1,544,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.2 %

Shares of NYSE PFE opened at $26.32 on Wednesday. The stock has a market cap of $149.04 billion, a PE ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37. The business has a 50-day moving average price of $27.07 and a 200 day moving average price of $28.52.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on PFE shares. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.